Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

Restricted access

Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and provides recommendations on the workup, diagnostic evaluation, and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients.

  • 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:730.

  • 2.

    National Cancer Institute. SEER 18, 2009-2013; Cancer Stat Facts: Acute Myeloid Leukemia (AML). Available at: https://seer.cancer.gov/statfacts/html/amyl.html. Accessed March 30, 2017.

    • Search Google Scholar
    • Export Citation
  • 3.

    Leone G, Pagano L, Ben-Yehuda D, Voso MT. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 2007;92:13891398.

    • Search Google Scholar
    • Export Citation
  • 4.

    Pagana L, Pulsoni A, Tosti ME. Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia. Br J Haematol 2001;112:109117.

    • Search Google Scholar
    • Export Citation
  • 5.

    Pulsoni A, Pagano L, Lo Coco F. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. Blood 2002;100:19721976.

    • Search Google Scholar
    • Export Citation
  • 6.

    Kayser S, Dohner K, Krauter J. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011;117:21372145.

    • Search Google Scholar
    • Export Citation
  • 7.

    Larson RA. Etiology and management of therapy-related myeloid leukemia. Hematology Am Soc Hematol Educ Program 2007:453459.

  • 8.

    Carney DA, Westerman DA, Tam CS. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia 2010;24:20562062.

    • Search Google Scholar
    • Export Citation
  • 9.

    Czader M, Orazi A. Therapy-related myeloid neoplasms. Am J Clin Pathol 2009;132:410425.

  • 10.

    Hosing C, Munsell M, Yazji S. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol 2002;13:450459.

    • Search Google Scholar
    • Export Citation
  • 11.

    Lenz G, Dreyling M, Schiegnitz E. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004;22:49264933.

    • Search Google Scholar
    • Export Citation
  • 12.

    Ferrara F, Mirto S. Serum LDH value as a predictor of clinical outcome in acute myelogenous leukaemia of the elderly. Br J Haematol 1996;92:627631.

    • Search Google Scholar
    • Export Citation
  • 13.

    Yamauchi T, Negoro E, Lee S. A high serum uric acid level is associated with poor prognosis in patients with acute myeloid leukemia. Anticancer Res 2013;33:39473951.

    • Search Google Scholar
    • Export Citation
  • 14.

    Cassileth PA, Sylvester LS, Bennett JM, Begg CB. High peripheral blast count in adult acute myelogenous leukemia is a primary risk factor for CNS leukemia. J Clin Oncol 1988;6:495498.

    • Search Google Scholar
    • Export Citation
  • 15.

    Bryant A, Sheppard D, Sabloff M. A single-institution analysis of the utility of pre-induction ejection fraction measurement in patients newly diagnosed with acute myeloid leukemia. Leuk Lymphoma 2015;56:135140.

    • Search Google Scholar
    • Export Citation
  • 16.

    Harris NL, Jaffe ES, Diebold J. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:38353849.

    • Search Google Scholar
    • Export Citation
  • 17.

    Cheson BD, Bennett JM, Kopecky KJ. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in acute myeloid leukemia. J Clin Oncol 2003;21:46424649.

    • Search Google Scholar
    • Export Citation
  • 18.

    Swerdlow SH, Campo E, Harris NL, eds. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed. Lyon, France: IARC; 2008.

  • 19.

    Arber DA, Orazi A, Hasserjian R. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:23912405.

    • Search Google Scholar
    • Export Citation
  • 20.

    Fernandez HF, Sun Z, Yao X. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009;361:12491259.

  • 21.

    Luskin MR, Lee JW, Fernandez HF. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood 2016;127:15511558.

    • Search Google Scholar
    • Export Citation
  • 22.

    Pautas C, Merabet F, Thomas X. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol 2010;28:808814.

    • Search Google Scholar
    • Export Citation
  • 23.

    Teuffel O, Leibundgut K, Lehrnbecher T. Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol 2013;161:192203.

    • Search Google Scholar
    • Export Citation
  • 24.

    Burnett AK, Russell NH, Hills RK. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 2015;125:38783885.

    • Search Google Scholar
    • Export Citation
  • 25.

    Holowiecki J, Grosicki S, Giebel S. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol 2012;30:24412448.

    • Search Google Scholar
    • Export Citation
  • 26.

    Fischer T, Stone RM, Deangelo DJ. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 2010;28:43394345.

    • Search Google Scholar
    • Export Citation
  • 27.

    Stone RM, Fischer T, Paquette R. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia 2012;26:20612068.

    • Search Google Scholar
    • Export Citation
  • 28.

    Stone RM, Mandrekar S, Sanford BL. The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18-60 with FLT3 mutations (muts): an international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603/RATIFY [Alliance]) [abstract]. Blood 2015;126:Abstract 6.

    • Search Google Scholar
    • Export Citation
  • 29.

    Willemze R, Suciu S, Meloni G. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. J Clin Oncol 2014;32:219228.

    • Search Google Scholar
    • Export Citation
  • 30.

    Bishop JF, Matthews JP, Young GA. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996;87:17101717.

    • Search Google Scholar
    • Export Citation
  • 31.

    Bishop JF, Matthews JP, Young GA. Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group. Leuk Lymphoma 1998;28:315327.

    • Search Google Scholar
    • Export Citation
  • 32.

    Weick JK, Kopecky KJ, Appelbaum FR. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996;88:28412851.

    • Search Google Scholar
    • Export Citation
  • 33.

    Mayer RJ, Davis RB, Schiffer CA. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896903.

    • Search Google Scholar
    • Export Citation
  • 34.

    Li W, Gong X, Sun M. High-dose cytarabine in acute myeloid leukemia treatment: a systematic review and meta-analysis. PLoS One 2014;9:e110153.

  • 35.

    Kern W, Estey EH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: review of three randomized trials. Cancer 2006;107:116124.

    • Search Google Scholar
    • Export Citation
  • 36.

    Bloomfield CD, Lawrence D, Byrd JC. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998;58:41734179.

    • Search Google Scholar
    • Export Citation
  • 37.

    Burnett AK, Russell NH, Hills RK. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol 2013;31:33603368.

    • Search Google Scholar
    • Export Citation
  • 38.

    Lowenberg B, Pabst T, Maertens J. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. Blood 2017;129:16361645.

    • Search Google Scholar
    • Export Citation
  • 39.

    Al-Ali HK, Brand R, van Biezen A. A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia 2007;21:19451951.

    • Search Google Scholar
    • Export Citation
  • 40.

    Smith M, Barnett M, Bassan R. Adult acute myeloid leukaemia. Crit Rev Oncol Hematol 2004;50:197222.

  • 41.

    Suciu S, Mandelli F, de Witte T. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003;102:12321240.

    • Search Google Scholar
    • Export Citation
  • 42.

    Slovak ML, Kopecky KJ, Cassileth PA. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:40754083.

    • Search Google Scholar
    • Export Citation
  • 43.

    Burnett AK, Wheatley K, Goldstone AH. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002;118:385400.

    • Search Google Scholar
    • Export Citation
  • 44.

    Cairoli R, Beghini A, Grillo G. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006;107:34633468.

    • Search Google Scholar
    • Export Citation
  • 45.

    Paschka P, Marcucci G, Ruppert AS. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B study. J Clin Oncol 2006;24:39043911.

    • Search Google Scholar
    • Export Citation
  • 46.

    Park SH, Chi HS, Min SK. Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. Leuk Res 2011;35:13761383.

  • 47.

    Lowenberg B, Pabst T, Vellenga E. Cytarabine dose for acute myeloid leukemia. N Engl J Med 2011;364:10271036.

  • 48.

    Dohner K, Schlenk RF, Habdank M. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005;106:37403746.

    • Search Google Scholar
    • Export Citation
  • 49.

    Schnittger S, Kohl TM, Haferlach T. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006;107:17911799.

    • Search Google Scholar
    • Export Citation
  • 50.

    Rollig C, Bornhauser M, Thiede C. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol 2011;29:27582765.

    • Search Google Scholar
    • Export Citation
  • 51.

    O'Farrell AM, Foran JM, Fiedler W. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003;9:54655476.

    • Search Google Scholar
    • Export Citation
  • 52.

    Rollig C, Serve H, Huttmann A. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol 2015;16:16911699.

    • Search Google Scholar
    • Export Citation
  • 53.

    Shah NP, Talpaz M, Deininger MW. Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study. Br J Haematol 2013;162:548552.

    • Search Google Scholar
    • Export Citation
  • 54.

    Zhang W, Konopleva M, Shi YX. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008;100:184198.

  • 55.

    Ravandi F, Arana Yi C, Cortes JE. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia 2014;28:15431545.

    • Search Google Scholar
    • Export Citation
  • 56.

    Ravandi F, Cortes JE, Jones D. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010;28:18561862.

    • Search Google Scholar
    • Export Citation
  • 57.

    Ravandi F, Alattar ML, Grunwald MR. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 2013;121:46554662.

    • Search Google Scholar
    • Export Citation
  • 58.

    Serve H, Krug U, Wagner R. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol 2013;31:31103118.

    • Search Google Scholar
    • Export Citation
  • 59.

    Altman JK, Perl AE, Cortes JE. Antileukemic activity and tolerability of ASP2215 80 mg and greater in FLT3 mutation-positive subjects with relapsed or refractory acute myeloid leukemia: results from a phase 1/2, open-label, dose-escalation/dose-response study. Blood 2015;126:321.

    • Search Google Scholar
    • Export Citation
  • 60.

    Hills RK, Gammon G, Trone D, Burnett AK. Quizartinib significantly improves overall survival in FLT3-ITD positive AML patients relapsed after stem cell transplantation or after failure of salvage chemotherapy: a comparison with historical AML database (UK NCRI data). Blood 2015;126:2557.

    • Search Google Scholar
    • Export Citation
  • 61.

    Aldoss I, Pullarkat V. Therapy-related acute myeloid leukemia with favorable cytogenetics: still favorable? Leuk Res 2012;36:15471551.

  • 62.

    Farag SS, Ruppert AS, Mrozek K. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol 2005;23:482493.

    • Search Google Scholar
    • Export Citation
  • 63.

    Lazenby M, Gilkes AF, Marrin C. The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial. Leukemia 2014;28:19531959.

    • Search Google Scholar
    • Export Citation
  • 64.

    Appelbaum FR, Gundacker H, Head DR. Age and acute myeloid leukemia. Blood 2006;107:34813485.

  • 65.

    Kantarjian H, O'Brien S, Cortes J. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006;106:10901098.

    • Search Google Scholar
    • Export Citation
  • 66.

    Klepin HD, Geiger AM, Tooze JA. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood 2013;121:42874294.

    • Search Google Scholar
    • Export Citation
  • 67.

    Sherman AE, Motyckova G, Fega KR. Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes. Leuk Res 2013;37:9981003.

    • Search Google Scholar
    • Export Citation
  • 68.

    Krug U, Rollig C, Koschmieder A. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet 2010;376:20002008.

    • Search Google Scholar
    • Export Citation
  • 69.

    Walter RB, Othus M, Borthakur G. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol 2011;29:44174423.

    • Search Google Scholar
    • Export Citation
  • 70.

    Gardin C, Turlure P, Fagot T. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 2007;109:51295135.

    • Search Google Scholar
    • Export Citation
  • 71.

    Gardin C, Chevret S, Pautas C. Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. J Clin Oncol 2013;31:321327.

    • Search Google Scholar
    • Export Citation
  • 72.

    Lowenberg B, Ossenkoppele GJ, van Putten W. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009;361:12351248.

    • Search Google Scholar
    • Export Citation
  • 73.

    Burnett AK, Russell NH, Hills RK. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012;30:39243931.

    • Search Google Scholar
    • Export Citation
  • 74.

    Castaigne S, Pautas C, Terre C. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012;379:15081516.

    • Search Google Scholar
    • Export Citation
  • 75.

    Amadori S, Suciu S, Stasi R. Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17). J Clin Oncol 2013;31:44244430.

    • Search Google Scholar
    • Export Citation
  • 76.

    Loke J, Khan JN, Wilson JS. Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia. Ann Hematol 2015;94:361373.

    • Search Google Scholar
    • Export Citation
  • 77.

    Kharfan-Dabaja MA, Hamadani M, Reljic T. Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol 2013;163:315325.

    • Search Google Scholar
    • Export Citation
  • 78.

    Li X, Xu SN, Qin DB. Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials. Ann Oncol 2014;25:455461.

    • Search Google Scholar
    • Export Citation
  • 79.

    Hills RK, Castaigne S, Appelbaum FR. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 2014;15:986996.

    • Search Google Scholar
    • Export Citation
  • 80.

    Kantarjian HM, Erba HP, Claxton D. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010;28:549555.

    • Search Google Scholar
    • Export Citation
  • 81.

    Burnett AK, Russell NH, Kell J. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010;28:23892395.

    • Search Google Scholar
    • Export Citation
  • 82.

    Burnett AK, Russell NH, Hunter AE. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood 2013;122:13841394.

    • Search Google Scholar
    • Export Citation
  • 83.

    Faderl S, Ravandi F, Huang X. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008;112:16381645.

    • Search Google Scholar
    • Export Citation
  • 84.

    Martinez-Cuadron D, Montesinos P, Oriol A. Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia. Ann Hematol 2014;93:4346.

    • Search Google Scholar
    • Export Citation
  • 85.

    Foran JM, Sun Z, Claxton DF. North American leukemia, Intergroup phase III randomized trial of single agent clofarabine as induction and post-remission therapy, and decitabine as maintenance therapy in newly-diagnosed acute myeloid leukemia in older adults (age ≥60 years): a trial of the ECOG-ACRIN Cancer Research Group [abstract]. Presented at the 2015 ASH Annual Meeting; December 5–8, 2015; Orlando, Florida. Abstract 217.

    • Search Google Scholar
    • Export Citation
  • 86.

    Foran JM, Sun Z, Claxton DF. Importance of achieving complete remission (CR) after intensive therapy for acute myeloid leukemia (AML) in older adults age ≥60 years: analysis of risk factors for early mortality and re-induction, and impact of quality of response on overall survival (OS) in the ECOG-ACRIN E2906 randomized trial [abstract]. Presented at the 2016 ASH Annual Meeting; December 3–6, 2016; San Diego, California. Abstract 613.

    • Search Google Scholar
    • Export Citation
  • 87.

    Fenaux P, Mufti GJ, Hellstrom-Lindberg E. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223232.

    • Search Google Scholar
    • Export Citation
  • 88.

    Fenaux P, Mufti GJ, Hellstrom-Lindberg E. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28:562569.

    • Search Google Scholar
    • Export Citation
  • 89.

    Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010;28:556561.

    • Search Google Scholar
    • Export Citation
  • 90.

    Issa JP, Garcia-Manero G, Giles FJ. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2’-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004;103:16351640.

    • Search Google Scholar
    • Export Citation
  • 91.

    Blum W, Garzon R, Klisovic RB. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A 2010;107:74737478.

    • Search Google Scholar
    • Export Citation
  • 92.

    Kantarjian HM, Thomas XG, Dmoszynska A. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012;30:26702677.

    • Search Google Scholar
    • Export Citation
  • 93.

    Burnett AK, Milligan D, Prentice AG. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007;109:11141124.

    • Search Google Scholar
    • Export Citation
  • 94.

    Faderl S, Ravandi F, Huang X. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 2012;118:44714477.

    • Search Google Scholar
    • Export Citation
  • 95.

    Pollyea DA, Kohrt HE, Gallegos L. Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia 2012;26:893901.

    • Search Google Scholar
    • Export Citation
  • 96.

    Pollyea DA, Zehnder J, Coutre S. Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica 2013;98:591596.

    • Search Google Scholar
    • Export Citation
  • 97.

    Cortes JE, Goldberg SL, Feldman EJ. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer 2015;121:234242.

    • Search Google Scholar
    • Export Citation
  • 98.

    Lancet JE, Cortes JE, Hogge DE. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood 2014;123:32393246.

    • Search Google Scholar
    • Export Citation
  • 99.

    Herr AL, Labopin M, Blaise D. HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia. Leukemia 2007;21:129135.

    • Search Google Scholar
    • Export Citation
  • 100.

    Storb R. Can reduced-intensity allogeneic transplantation cure older adults with AML? Best Pract Res Clin Haematol 2007;20:8590.

  • 101.

    Estey E, de Lima M, Tibes R. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007;109:13951400.

    • Search Google Scholar
    • Export Citation
  • 102.

    Martino R, Valcarcel D, Brunet S. Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission. Bone Marrow Transplant 2008;41:3338.

    • Search Google Scholar
    • Export Citation
  • 103.

    Kurosawa S, Yamaguchi T, Uchida N. Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission. Biol Blood Marrow Transplant 2011;17:401411.

    • Search Google Scholar
    • Export Citation
  • 104.

    Farag SS, Maharry K, Zhang MJ. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant 2011;17:17961803.

    • Search Google Scholar
    • Export Citation
  • 105.

    Devine SM, Owzar K, Blum W. Phase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced-intensity conditioning regimen: results from Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol 2015;33:41674175.

    • Search Google Scholar
    • Export Citation
  • 106.

    Versluis J, Hazenberg CL, Passweg JR. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. Lancet Haematol 2015;2:e427436.

    • Search Google Scholar
    • Export Citation
  • 107.

    Jurcic JG. Androgen maintenance therapy for acute myeloid leukemia. J Clin Oncol 2017;35:381383.

  • 108.

    Pigneux A, Bene MC, Guardiola P. Addition of androgens improves survival in elderly patients with acute myeloid leukemia: a GOELAMS study. J Clin Oncol 2017;35:387393.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 1 0 0
Full Text Views 8430 3819 175
PDF Downloads 2894 1398 80
EPUB Downloads 0 0 0